Moderna and Merck collaborated on a program that, after about a decade of work, produced a Phase 3 study described in the source as the first to show a customized mRNA vaccine could improve outcomes in melanoma. The company presented the trial at the European Society for Medical Oncology meeting, and the source reported investigators released the data there.
Stéphane Bancel, Moderna’s CEO, told STAT he felt the result was deeply meaningful. He said the project had been a long haul — roughly 10 years of development — and that many observers in the field once doubted whether a personalized cancer vaccine could succeed. The team’s persistence, he said, produced a clinical result that validated those efforts. The source quoted him describing the experience as “really special,” reflecting both scientific and human contributions over years.
Bancel told STAT that Moderna intends to “go as fast as we can” in seeking FDA approval for intismeran. The source reported the company planned to pursue regulatory filings following the Phase 3 outcome. The interview was conducted on the sidelines of the ESMO annual meeting in Madrid; the published excerpt noted the conversation was wide-ranging but condensed and edited for clarity.
The source did not provide specific regulatory timing, filing contents, or details about the exact approvals Moderna will seek. It also did not list proposed labeling, intended patient populations for an initial submission, or the exact submission pathway the company will follow. Those specifics were not reported in the available excerpt.
The source placed the Phase 3 success in the context of persistent skepticism about cancer vaccines. Many groups had previously attempted similar approaches with limited success, the article noted, and researchers outside of Moderna had long been cautious about the likelihood of a durable vaccine effect in oncology. Moderna’s program, the source said, benefited from years of internal research plus a strategic collaboration with Merck that helped advance development.
Bancel framed the result as the culmination of collective work — not just Moderna’s — by investigators, collaborators, and the company’s research teams. The source described the therapy as a customized mRNA-based vaccine; however, it did not provide specific trial design elements, dosing regimens, primary or secondary endpoints, statistical results, or subgroup analyses in the excerpt made available.
The published excerpt left several operational and scientific questions unanswered. The source did not report detailed efficacy metrics, safety data, or the Phase 3 study’s sample size and endpoints. It also did not include granular information about manufacturing scale-up plans, payer negotiations, or planned label claims.
Regulatory timing remains unspecified in the source; although Bancel said the company intends to move quickly toward an FDA submission, the article did not report precise submission dates, the pathway Moderna will pursue, or anticipated review timelines. The excerpt similarly omitted long-term follow-up data and any discussion of how broadly the vaccine might be applied beyond the melanoma setting.
Investigators reported the Phase 3 presentation at ESMO, and the company emphasized the role of the partnership with Merck in reaching this point. The source indicated the interview was subscriber-exclusive and that further details from the conversation and additional reporting were behind a STAT+ paywall.
Limitations documented in the source therefore include the lack of complete trial data and missing regulatory specifics in the public excerpt. The next concrete milestones cited by the company in the available text were pursuing regulatory filings and continuing follow-up work; the source did not list other milestone dates or further scientific programs in detail.
The public record in the source ends on those practical next steps and on the outstanding questions about precise data and timelines that remain to be reported as Moderna and its collaborators advance intismeran toward potential approval.